Gilead Sciences Inc

XNASHealth care

Last traded price · USD

$168.21

+0.44%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 15:21 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $167.47
Volume: 4,142
Day's high: —
Day's low: —

In brief

Gilead Sciences Inc is a health care company listed on Nasdaq, valued at about $208.64B.
Its shares closed at $167.47 on 3 Nov 2026, up 37.2% over the past year.
From India you can buy GILD in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Gilead Sciences Inc (GILD) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole GILD share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade GILD options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +15.8% (SPY −2.6%, XLV +9.9%). 3 months: +23.8% (SPY −2.2%, XLV +13.5%). 1 year: +37.2% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: GILD, SPY and XLV · as of 3 Nov 2026
4.7% below its 52-week high
Closed at $167.47 on 3 Nov 2026: 4.7% below the 52-week high of $175.65 (30 Oct 2026) and 43.3% above the low of $116.88 (5 Jan 2026).
Daily price bars, split-adjusted · as of 3 Nov 2026
Above its 50- and 200-day averages
The 3 Nov 2026 close of $167.47 was 10.3% above its 50-day average ($151.77) and 19.3% above its 200-day average ($140.34). It has closed above the 200-day for 62 sessions, since 7 Aug 2026. The 50-day average crossed above the 200-day on 27 Aug 2026, 47 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
Next ex-dividend date: 15 Dec 2026
$0.82 a share, payable 30 Dec 2026; unchanged from the previous payment (ex-date 15 Sep 2026).
Corporate actions record · as of 4 Nov 2026
Short interest at 1.6% of shares outstanding
20.3M shares were sold short at the 15 Oct 2026 settlement, 1.6% of the 1.24B shares outstanding; covering them would take 3.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 3 Nov 2026 close

1 month+15.8%

6 months+25.5%

1 year+37.2%

5 years+148.4%

Newswire

About

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Website

Notable moves

June 20, 2024
+8.46%
January 22, 2024
−10.15%
October 28, 2022
+12.92%

Gilead Sciences Inc

XNASHealth care

Last traded price · USD

$168.21

+0.44%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 15:21 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $167.47
Volume: 4,142
Day's high: —
Day's low: —

In brief

Gilead Sciences Inc is a health care company listed on Nasdaq, valued at about $208.64B.
Its shares closed at $167.47 on 3 Nov 2026, up 37.2% over the past year.
From India you can buy GILD in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Gilead Sciences Inc (GILD) shares from India?

Do I need the price of a whole GILD share to invest?

How much can I invest in US stocks in a year?

Can I trade GILD options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +15.8% (SPY −2.6%, XLV +9.9%). 3 months: +23.8% (SPY −2.2%, XLV +13.5%). 1 year: +37.2% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: GILD, SPY and XLV · as of 3 Nov 2026
4.7% below its 52-week high
Closed at $167.47 on 3 Nov 2026: 4.7% below the 52-week high of $175.65 (30 Oct 2026) and 43.3% above the low of $116.88 (5 Jan 2026).
Daily price bars, split-adjusted · as of 3 Nov 2026
Above its 50- and 200-day averages
The 3 Nov 2026 close of $167.47 was 10.3% above its 50-day average ($151.77) and 19.3% above its 200-day average ($140.34). It has closed above the 200-day for 62 sessions, since 7 Aug 2026. The 50-day average crossed above the 200-day on 27 Aug 2026, 47 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
Next ex-dividend date: 15 Dec 2026
$0.82 a share, payable 30 Dec 2026; unchanged from the previous payment (ex-date 15 Sep 2026).
Corporate actions record · as of 4 Nov 2026
Short interest at 1.6% of shares outstanding
20.3M shares were sold short at the 15 Oct 2026 settlement, 1.6% of the 1.24B shares outstanding; covering them would take 3.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 3 Nov 2026 close

1 month+15.8%

6 months+25.5%

1 year+37.2%

5 years+148.4%

Newswire

About

Website

Notable moves

June 20, 2024
+8.46%
January 22, 2024
−10.15%
October 28, 2022
+12.92%

Gilead Sciences Inc

Gilead Sciences Inc in brief

Ahead of SPY and its sector fund XLV over 1 year

4.7% below its 52-week high

Above its 50- and 200-day averages

Next ex-dividend date: 15 Dec 2026

Short interest at 1.6% of shares outstanding

Gilead Sciences Inc

Gilead Sciences Inc in brief

Ahead of SPY and its sector fund XLV over 1 year

4.7% below its 52-week high

Above its 50- and 200-day averages

Next ex-dividend date: 15 Dec 2026

Short interest at 1.6% of shares outstanding